Incretin Use May Up Pancreatic CA Risk, but Only in Short Term

This article originally appeared here.
Share this content:
Incretin Use May Up Pancreatic CA Risk, but Only in Short Term
Incretin Use May Up Pancreatic CA Risk, but Only in Short Term

THURSDAY, Nov. 12, 2015 (HealthDay News) -- The risk of pancreatic cancer is increased in recent starters of incretins, but the elevated risk drops to baseline levels with prolonged use, according to a study published online Nov. 5 in Diabetes, Obesity and Metabolism.

Lotte M. Knapen, from Maastricht University Medical Center in the Netherlands, and colleagues examined the correlation between incretin agent use and risk of pancreatic cancer in a retrospective population-based cohort study. A total of 182,428 patients with at least one non-insulin antidiabetic drug (NIAD) prescription were matched to control patients without diabetes. The researchers also used a new user design to estimate the hazard ratio of pancreatic cancer in 28,370 incretin users compared with patients without diabetes and other NIAD-treated patients

The researchers found that the risk of pancreatic cancer was increased fourfold with current NIAD use (hazard ratio, 4.28; 95 percent confidence interval, 3.49 to 5.24). Current incretin users had almost double the risk compared with controls. Compared to controls with diabetes, incretin use was not associated with pancreatic cancer (hazard ratio, 1.36; 95 percent confidence interval, 0.94 to 1.96). However, in the new user design, there was a correlation between incretin use and pancreatic cancer. The risk of pancreatic cancer almost doubled in recent starters of incretin in cohorts with both prevalent and incident users of anti-diabetic drugs; with prolonged use, the risk decreased to baseline levels.

"The presence of considerable confounding by disease severity and the lack of duration of use relationship do not support a causal explanation for the association between incretin agents and pancreatic cancer," the authors write.

Some authors disclosed institutional funding from industry, including pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

No Long-Term Health Issues for Infants With Isolated Oral Clefts

No Long-Term Health Issues for Infants With Isolated ...

However, cleft palate associated with increased risk for developmental problems

T2DM Predicts Mortality in Patients With Heart Failure

T2DM Predicts Mortality in Patients With Heart Failure

Type 2 diabetes mellitus predicts mortality, regardless of presence of ischemic heart disease

Unmet Needs for Non-HIV Care in Men Who Have Sex With Men

Unmet Needs for Non-HIV Care in Men Who ...

About 23 percent have unmet need for dental care, 19 percent have unmet need for eye or vision care

is free, fast, and customized just for you!

Already a member?

Sign In Now »